RELATION OF KIDNEY BIOPSY FINDINGS TO CLINICAL OUTCOMES IN PATIENTS WITH LUPUS NEPHRITIS TREATED WITH AN ANTAGONISTIC ANTI-CD40 ANTIBODY (BI 655064)

被引：0
|
作者：
Bajema, Ingeborg [1 ]
Schumacher, Helmut
Steffgen, Juergen [2 ]
Deutschel, Simone [3 ]
Jayne, David [4 ]
机构：
[1] Univ Med Ctr Groningen, Pathol & Med Biol, Groningen, Netherlands
[2] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[3] Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
[4] Univ Cambridge, Dept Med, Cambridge, England
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
4570
引用
收藏
页码：I308 / I309
页数：2
相关论文
共 29 条
  • [1] SAFETY AND EFFICACY OF BI 655064, AN ANTAGONISTIC ANTI-CD40 ANTIBODY IN RHEUMATOID ARTHRITIS (RA) PATIENTS
    Daniluk, S.
    Ptaszynski, R.
    Mueller-Ladner, U.
    Petrikova, A.
    Kellner, H.
    Dokoupilova, E.
    Kwiatkowska, B.
    Alten, R.
    Schwabe, C.
    Rosenstock, B.
    Doan, T.
    Thiedmann, R.
    Fleischer, F.
    Hilbert, J.
    Visvanathan, S.
    Padula, S.
    Steffgen, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 718 - 718
  • [2] A RANDOMISED DOSE RANGING, PLACEBO-CONTROLLED, PHASE II STUDY ASSESSING THE EFFICACY AND SAFETY OF BI 655064, AN ANTAGONISTIC ANTI-CD40 ANTIBODY, IN PATIENTS WITH LUPUS NEPHRITIS
    Jayne, D.
    Steffgen, J.
    Romero-Diaz, J.
    Amano, H.
    Noppakun, K.
    Gomez, H. M.
    Recto, R.
    Belsack, V.
    Fagan, N.
    Padula, S.
    Revollo, I.
    Wu, J.
    Visvanathan, S.
    Furie, R.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 589 - 590
  • [3] Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti-CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial
    Jayne, David R.
    Steffgen, Juergen
    Romero-Diaz, Juanita
    Bajema, Ingeborg
    Boumpas, Dimitrios T.
    Noppakun, Kajohnsak
    Amano, Hirofumi
    Gomez, Harold Michael
    Satirapoj, Bancha
    Avihingsanon, Yingyos
    Chawanasuntorapoj, Ratana
    Madero, Magdalena
    Naumnik, Beata
    Recto, Rhona
    Fagan, Nora
    Revollo, Ivette
    Wu, Jing
    Visvanathan, Sudha
    Furie, Richard
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 (11) : 1983 - 1993
  • [4] A RANDOMISED DOSE RANGING, PLACEBO-CONTROLLED, PHASE II STUDY ASSESSING THE EFFICACY AND SAFETY OF BI 655064, AN ANTAGONISTIC ANTI-CD40 ANTIBODY, IN PATIENTS WITH LUPUS NEPHRITIS
    Jayne, David
    Furie, Richard
    Romero-Diaz, Juanita
    Amano, Hirofumi
    Noppakun, Kajohnsak
    Michael Gomez, Harold
    Recto, Rhona
    Belsack, Valerie
    Fagan, Nora
    Padula, Steven
    Revollo, Ivette
    Wu, Jing
    Visvanathan, Sudha
    Diaeresis, Jurgen
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36
  • [5] TREATMENT WITH BI 655064 (ANTAGONISTIC ANTI-CD40 ANTIBODY) MODULATES BIOMARKERS ASSOCIATED WITH RHEUMATOID ARTHRITIS (RA)
    Visvanathan, S.
    Ramanujam, M.
    Schoelch, C.
    Vinisko, R.
    Mueller-Ladner, U.
    Padula, S.
    Fine, J. S.
    Steffgen, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 517 - 517
  • [6] Treatment with BI 655064 (Antagonistic Anti-CD40 Antibody) Modulates Clinical and Biomarker Parameters Associated with Rheumatoid Arthritis (RA)
    Visvanathan, Sudha
    Ramanujam, Meera
    Schoelch, Corinna
    Baum, Patrick
    Vinisko, Richard
    Thiedmann, Ralf
    Mueller-Ladner, Ulf
    Daniluk, Stefan
    Ptaszynski, Rafal
    Padula, Steven
    Fine, Jay S.
    Steffgen, Juergen
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [7] SAFETY, TOLERABILITY, PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF BI 655064, AN ANTAGONISTIC ANTI-CD40 ANTIBODY IN HEALTHY VOLUNTEERS
    Schwabe, C.
    Wagner, F.
    Filler, I.
    Albulescu, M.
    Rose, P.
    Emerson, B.
    Doan, T.
    Rosenstock, B.
    Joseph, D.
    Hilbert, J.
    Scholch, C.
    Habeck, J.
    Thiedmann, R.
    Padula, S.
    Steffgen, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 484 - 484
  • [8] Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases
    Albach, Fredrik N.
    Wagner, Frank
    Hueser, Andreas
    Igel, Julia
    Joseph, David
    Hilbert, James
    Schoelch, Corinna
    Padula, Steven J.
    Steffgen, Jeurgen
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (02) : 161 - 169
  • [9] Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases
    Fredrik N. Albach
    Frank Wagner
    Andreas Hüser
    Julia Igel
    David Joseph
    James Hilbert
    Corinna Schoelch
    Steven J. Padula
    Jürgen Steffgen
    [J]. European Journal of Clinical Pharmacology, 2018, 74 : 161 - 169
  • [10] Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti-CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases
    Schwabe, Christian
    Rosenstock, Bernd
    Doan, Thi
    Hamilton, Paul
    Dunbar, P. Rod
    Eleftheraki, Anastasia G.
    Joseph, David
    Hilbert, James
    Schoelch, Corinna
    Padula, Steven J.
    Steffgen, Juergen
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (12): : 1566 - 1577
123